Boehringer Ingelheim and Lilly announced data from a pooled analysis of two Phase 2b trials of empagliflozin, showing a reduction in systolic blood pressure independent of changes in blood glucose and ...

The researchers found that in the pooled analysis, bone fracture AEs were reported in 119 of 4221 patients (2.8%) randomized to empagliflozin 10mg, 105 of 4,196 patients (2.5%) randomized to ...

Pooled analysis in adults with type 2 diabetes presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting Empagliflozin is part of a class of drugs being investigated ...

Ingelheim, Germany and Indianapolis, US, 16 September, 2014 – Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study ...

Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 78-week Phase III clinical trial of the investigational compound empagliflozin * as an add-on to basal insulin in people ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Whether already on metformin or ...

Please provide your email address to receive an email when new articles are posted on . Study participants with type 2 diabetes receiving the SGLT2 inhibitor empagliflozin had a lower-limb amputation ...

The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes. Boehringer Ingelheim and Lilly announced positive topline results from a phase 3 trial evaluating the ...

Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ...

In 2022, the company had announced that it had received the CDSCO’s approval to market its innovator cardiac drug Jardiance (empagliflozin) in India(Mint) New Delhi: After giving the nod for the ...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. Statistical ...